The launch of Avigan 200 mg tablets in India announced by Dr Reddy’s Laboratories Limited .The launch is a important part of the global licensing agreement with the Fujifilm Toyama Chemical Co. Ltd., that grants the exclusive rights to the Indian drug makers to manufacture, sell and distribute the tablets across India, said M V Ramana, CEO of Branded Markets (India and Emerging Markets), Dr Reddy’s Laboratories.
The Avigan (Favipiravir) tablets has got approval by the Drugs Controller General of India (DCGI) for treating the patients affected with mild to moderate coronavirus disease.
While speaking to the reporters, Ramana said that,”We are pleased to bring this important innovator medicine to the patients in India. The need for high quality and efficacy, affordability and better disease management are key priorities for us. We believe that Aviganwould provide an effective treatment option to the COVID-19 impacted patients in India.”.
Avigan comes in a therapy pack inclusive of 122 tablets with a two year shelf life.
To ensure accelerated access to the medicine, Dr Reddy laboratories has initiated a free home delivery service in 42 cities in the country to ensure accelerated access to the medicine and also a Helpline Center between 9 am to 9 pm IST from Monday to Saturday.
Ramana further added that currently they are importing the drug from Japan and soon it will manufacture in India.
Replying to the query, he stated that they have already approached the regulatory authorities of two or three countries including the US seeking approvals to sell the drug and seek the fast track approvals from them once trials are completed.
Dr Reddy’s is all set to launch Remdesivir, another Covid-19 treatment drug in the first week of September, he informed.
